Literature DB >> 8700551

Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract.

A Suzuki1, A Matsuzawa, T Iguchi.   

Abstract

Suppression of apoptosis by Bcl-2, an oncogene product, has been previously reported. Although the down regulation of Bcl-2 has been encountered in various types of apoptosis, the time course of changes in the expression of Bcl-2 has yet to be determined. In the present study, we established and analysed an in vivo model of apoptosis. The mouse male reproductive tract, specifically the prostate and epididymis, which is regulated by sex steroid hormones, especially testosterone, showed regression induced by chromosomal DNA fragmentation, apoptotic cell death, after gonadectomy. Following this apoptosis, down regulation of Bcl-2 and the new expression of Fas were seen. Using functional Fas-lacking mice, we demonstrated that this regression of the male reproductive tract is triggered by Fas-mediated apoptosis. In addition, time course experiments revealed that down regulation of Bcl-2 when apoptosis occurs heralds Fas expression. We propose here that apoptotic death signal transduction in total involve, a number of steps, the first and most important of which is down regulation of Bcl-2.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8700551

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Mitochondrial regulation of cell death: mitochondria are essential for procaspase 3-p21 complex formation to resist Fas-mediated cell death.

Authors:  A Suzuki; Y Tsutomi; N Yamamoto; T Shibutani; K Akahane
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

2.  AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR.

Authors:  Pengfei Li; Heehyoung Lee; Shaodong Guo; Terry G Unterman; Guido Jenster; Wenlong Bai
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

3.  Effect of Modulation of hnRNP L Levels on the Decay of bcl-2 mRNA in MCF-7 Cells.

Authors:  Mi-Hyun Lim; Dong-Hyoung Lee; Seung Eun Jung; Dong-Ye Youn; Chan Sun Park; Jeong-Hwa Lee
Journal:  Korean J Physiol Pharmacol       Date:  2010-02-28       Impact factor: 2.016

4.  Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis.

Authors:  S Srikanth; C C Franklin; R C Duke; R S Kraft
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

5.  TNF is necessary for castration-induced prostate regression, whereas TRAIL and FasL are dispensable.

Authors:  Jennifer S Davis; Kent L Nastiuk; John J Krolewski
Journal:  Mol Endocrinol       Date:  2011-02-03

6.  Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas.

Authors:  Howard C Crawford; Charles R Scoggins; M Kay Washington; Lynn M Matrisian; Steven D Leach
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 7.  Why are epididymal tumours so rare?

Authors:  Ching-Hei Yeung; Kai Wang; Trevor G Cooper
Journal:  Asian J Androl       Date:  2012-04-23       Impact factor: 3.285

8.  Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate.

Authors:  Otabek Imamov; Andrea Morani; Gil-Jin Shim; Yoko Omoto; Christina Thulin-Andersson; Margaret Warner; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-08       Impact factor: 11.205

9.  Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide.

Authors:  M J Campbell; M Dawson; H P Koeffler
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

10.  In vivo MRI volumetric measurement of prostate regression and growth in mice.

Authors:  Kent L Nastiuk; Hui Liu; Mark Hamamura; L Tugan Muftuler; Orhan Nalcioglu; John J Krolewski
Journal:  BMC Urol       Date:  2007-07-24       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.